ライフサイエンスコーパス: EFS

1 EFS and overall survival at 2 years were 39% (95% confid

2 EFS and overall survival were compared using the log-ran

3 EFS at 3 years was 60%, (70% RRMS).

4 EFS caused vasodilatation in arteries constricted with 1

5 EFS in the GO arm was not significantly different compar

6 EFS increased force and phosphorylation of RLC, CPI-17 a

7 EFS is a weak surrogate for OS and is not suitable for u

8 EFS was best with matched sibling donors, myeloablative

9 EFS was defined as the time from random assignment to th

10 EFS was defined as time from date of diagnosis to progre

11 EFS was evaluated in comparison with 415 historical cont

12 EFS was higher for patients with infratentorial tumors w

13 EFS was higher with >/= 90% resection (45.9% +/- 4.3%) t

14 EFS was not associated with tumor grade (P= 0.98), histo

15 ing 5-year rates: FFS (52% vs 70%, P = .02), EFS (68% vs 86%, P = .02), TFS (76% vs 94%, P < .01), an

16 In the PTGS2-low group (n = 100), EFS was lower in the celecoxib arm (HR, 3.01; 95% CI, 1.

17 Studies that addressed EFS or OS by MRD status in patients with ALL were includ

18 ion of the U.S. Food and Drug Administration EFS program has been successful, but residual significan

19 LN) 2010 intermediate I prognostic risk AML (EFS, 26% +/- 4 vs 40% +/- 5 at 4 years; Cox P = .002) an

20 GR group (n = 86) were an OS of 66.8% and an EFS of 62.5%.

21 -PR group (n = 43) had an OS of 74.8% and an EFS of 73.4%.

22 allo-HSCT (late nonresponders) still had an EFS of 50% and OS of 63%, which in principle justifies a

23 survival was 98% versus 86% ( P = .003), and EFS was 95% versus 83% ( P = .03), respectively.

24 isolated adrenal metastases; P = 0.816) and EFS (9.39 vs 9.59 months; P = 0.87) were similar.

25 cell, T cell, Philadelphia chromosome), and EFS and OS.

26 or German Hodgkin Study Group risk group and EFS, before or after adjusting for PET score (all P > .4

27 In pediatric patients, OAS and EFS did not differ significantly between patients with a

28 ed donors was associated with reduced OS and EFS .

29 Nevertheless, OS and EFS at 3 years for patients >=18 years were 76% and 69%,

30 by risk group demonstrated decreased OS and EFS in the standard-risk group only (HR, 1.9; 95% CI, 1.

31 The optimal SUVmax for predicting pCR and EFS was, however, specific to the treatment regimen.

32 to evaluate the association between pCR and EFS/OS and to predict long-term survival outcomes based

33 d OS were 84.5% and 87.0%, respectively, and EFS was 100% and 82.1% in low- and high-risk patients.

34 veals no differences in overall survival and EFS between the control (EFS, 35% +/- 3 [standard error]

35 s, clofarabine improved overall survival and EFS for European Leukemia Net (ELN) 2010 intermediate I

36 resection (ie, anatomic v partial/wedge) and EFS ( P = .67).

37 A better EFS was associated with negative lymph node status ( P <

38 to chlorambucil led to significantly better EFS (hazard ratio, 0.54; 95% CI, 0.38 to 0.77).

39 90% was associated with significantly better EFS and lower CILP.

40 ransplant resulted in a significantly better EFS than single transplant.

41 ed dose-dense group had significantly better EFS than the control group (HR, 0.79; 95% CI, 0.63-0.99;

42 ed that earlier use of HD-araC led to better EFS and OS in AAML0431 than in past COG studies.

43 H deep sequencing was associated with better EFS (P = .034).

44 erapy (HR, 0.39) were associated with better EFS.

45 Both EFS (hazard ratio [HR], 1.6; 95% CI, 1.2 to 2.1; P = .00

46 atment effects (hazard ratios [HRs]) on both EFS and OS (trial level).

47 Contractions induced by EFS were reduced by an Ano1 channel antagonist, abolishe

48 Five-year CILP, EFS, and OS rates for patients in A3973 with incomplete

49 In comparison, 5-year CILP, EFS, and OS rates for patients in ANBL0532 who were rand

50 ceiving radiotherapy (n = 323), 5-year CILP, EFS, and OS rates were 11.2% +/- 1.8%, 56.2% +/- 3.4%, a

51 served cardiac function without compromising EFS and OS or increasing noncardiac toxicities.

52 verall survival and EFS between the control (EFS, 35% +/- 3 [standard error] at 4 years) and clofarab

53 e aberrations (SCAs); only 1p loss decreased EFS (5-year EFS +/- SD in patients 1p loss and no 1p los

54 arable, we observed a trend toward decreased EFS for patients assigned to receive fewer doses of cisp

55 diotoxicity may be associated with decreased EFS and OS.

56 e/FLT3 without internal-tandem duplications (EFS, 18% +/- 5 vs 40% +/- 7; Cox P < .001).

57 lasmic calcium concentration in hASCs during EFS, our findings also suggest that primary cilia may po

58 cial calcium-signaling nexus in hASCs during EFS.

59 Pediatric LPHL has excellent EFS with chemotherapy that is less intensive than standa

60 G ABFM regimen with C-MTX provided excellent EFS and OS without cranial radiation.

61 ratio, 1.97) were independent risk factors (EFS).

62 astic (n = 5) medulloblastoma ( P < .001 for EFS; P = .001 for OS).

63 A hazard ratio of 1.3 for EFS associated with IME compared with CME was observed b

64 Summary risk estimates for EFS, OS, and CIR (ALL only) were calculated with random-

65 was not a significant prognostic factor for EFS (P = .263; HR, 1.312).

66 Positive predictive factors for EFS were age younger than 10 years and tumor size less t

67 ease were independent prognostic factors for EFS.

68 pCR and the corresponding treatment HRs for EFS and OS.

69 Factors predictive for EFS by multivariable analysis were baseline MTV (bMTV) (

70 k factors of 9 evaluated were predictive for EFS: age at transplantation and donor type.

71 were evaluated by HTS and FC for event-free (EFS) and overall survival (OS).

72 CILP (primary end point) and event-free (EFS) and overall survival (OS; secondary end points) wer

73 n Most patients with stage III FHWT had good EFS/overall survival with DD4A and radiation therapy.

74 d linear regression of log(HR)-OS on log(HR)-EFS.

75 ients with DLBCL alone, but nearly identical EFS (HR = 1.00) and OS (HR = 0.84) compared with patient

76 stology-based postoperative therapy improved EFS and OS and preservation of renal parenchyma compared

77 Augmentation of therapy improved EFS for patients with favorable histology Wilms tumor an

78 adjuvant therapy is associated with improved EFS/OS in patients with TNBC who received neoadjuvant th

79 on but significantly reduces RR and improves EFS in patients with high CD33 expression, which suggest

80 we investigate the role of primary cilia in EFS-enhanced osteogenic response of human adipose-derive

81 There was no significant difference in EFS across trials according to number of prior treatment

82 e thresholds that resulted in differences in EFS.

83 studies suggested substantial improvement in EFS and OS for pCR versus non-pCR [EFS HR (95% confidenc

84 Overall, the improvement in EFS for pCR vs non-pCR was substantial: HR, 0.37 (95% pr

85 We found no improvement in EFS with more extensive or serial resections.

86 id tissue lymphoma; however, improvements in EFS and progression-free survival did not translate into

87 stage, 1q gain was associated with inferior EFS (stage I, 85% v 95%; P = .0052; stage II, 81% v 87%;

88 High PET score was associated with inferior EFS, before (P < .001) and after adjustment (P = .01) fo

89 >/= 90% resection was associated with longer EFS after adjustment for MYCN amplification or diploidy

90 ts with Myc+ DLBCL had a significantly lower EFS.

91 e CR compared with those who did not (median EFS, 7.6 vs 0.8 months; P < .0001; median OS, 20.0 vs 5.

92 The 12-month EFS for the 42 evaluable patients enrolled in AOST0221 w

93 The 6-month EFS for the bevacizumab arm was 54.6% (95% CI, 39.8% to

94 At a median follow-up of 58.7 months, EFS and OS were 84.5% and 87.0%, respectively, and EFS w

95 of the cholinesterase inhibitor neostigmine, EFS led to an additional increase in phosphorylation of

96 comparator model specified that the observed EFS rate should not be significantly < 92%.

97 The chance of EFS was higher in patients with successful CD4(+) IR (HR

98 tion model by determining the correlation of EFS with OS (patient level) and the correlation of treat

99 At the patient level, the correlation of EFS with OS was 0.43 (95% CI, 0.42 to 0.44) as measured

100 lia seem to functionally modulate effects of EFS-induced cellular calcium oscillations.

101 alysis revealed a significant improvement of EFS by midostaurin (hazard ratio [HR], 0.58; 95% CI, 0.4

102 did not meet its early primary end point of EFS, mainly as a result of a higher early death rate in

103 node and LOH status was highly predictive of EFS and should be considered as a potential prognostic m

104 ry endpoints were toxicity and predictors of EFS and overall survival (OS).

105 33 therapy significantly reduced the risk of EFS events in patients < 36 months of age compared with

106 We evaluated the surrogacy of EFS for OS using a 2-stage meta-analytic validation mode

107 Impacts on EFS were equivalent whether the incident cardiotoxicity

108 statistically significant factor for OAS or EFS in the total cohort or in pediatric patients.

109 ere were no significant differences in OS or EFS between patients with and without concomitant extra-

110 conditioning regimen did not influence OS or EFS.

111 MAC is associated with better OS, EFS, and DFS.

112 tients had viable tumor and a worse outcome (EFS: 50%; P = 0.01).

113 Overall EFS (+/- SE) was 72.6 +/- 5.4% at 1 year, 57.6 +/- 6.2%

114 vement in EFS and OS for pCR versus non-pCR [EFS HR (95% confidence interval): 0.24 (0.20-0.29); OS:

115 xib use was an independent predictor of poor EFS, distant relapse-free survival, and OS.

116 BMI was significantly associated with poorer EFS and OS (RR: 1.36; 95% CI: 1.16, 1.60 and RR: 1.56; 9

117 Gain of 1q remained associated with poorer EFS in tumor subsets limited to either intermediate-risk

118 r notable aberrations associated with poorer EFS included MYCN gain and TP53 loss.

119 The association of 1q gain with poorer EFS retained significance in multivariable analysis adju

120 cisplatin had improved 5-year postinduction EFS (90.7% v 81.2%, P = .14).

121 tly associated with decreasing postoperative EFS ( P < .01).

122 ly nonresponders) had the poorest prognosis (EFS, 22%).

123 nteric small arteries of anaesthetized rats, EFS failed to stimulate major dilatation via sensory-mot

124 , patients with stage 2 tumors had a reduced EFS in both age groups (5-year EFS +/- SD, 84% +/- 3% in

125 ially 11q loss) are risk factors for reduced EFS and OS in those > 18months.

126 0(-2) or greater after induction had reduced EFS (56%), and their MRD persisted until allo-HSCT more

127 was found in OS, but a significantly reduced EFS was noted in the small group of patients who receive

128 d multiple trials or cohorts, which reported EFS/OS results by pCR in patients with early-stage TNBC.

129 improvements that have been made to the U.S. EFS ecosystem and outlines potential approaches to addre

130 consolidated per protocol by autologous SCT, EFS and OS of 23 patients were 30% +/- 10% and 78% +/- 9

131 Before termination of autologous SCT, EFS rates of patients in the very-high- (n = 17), high-

132 BCL and other indolent lymphomas had similar EFS (HR = 1.19) and OS (HR = 1.09) compared with patient

133 ABVD8 and BEACOPP4+4 resulted in similar EFS and OS in patients with high-risk advanced-stage HL.

134 Despite SOM-EFS selecting only 14 volatiles compared to 78 for PLS-D

135 These findings introduce SOM-EFS as a powerful non-linear exploratory data analysis a

136 aps and entropy-based feature selection (SOM-EFS) and PLS-DA-VID to identify discriminant compounds i

137 volatiles compared to 78 for PLS-DA-VID, SOM-EFS proved more effectively discriminant and improved th

138 The effects of electrical field stimulation (EFS) and drugs on artery diameter and blood flow were re

139 rostimulation by electric field stimulation (EFS) in bovine tracheal smooth muscle.

140 Electrical field stimulation (EFS) in the presence of L-NNA and MRS 2500 enhanced ICC-

141 Electrical field stimulation (EFS) of wild-type (WT) mouse ileum induced nNOS S1412 ph

142 ination of the electrical field stimulation (EFS) with data acquisition in spatially separated areas

143 Electrical field stimulation (EFS), which releases ACh from nerves, increased force an

144 ial sensor for electrical field stimulation (EFS)-enhanced osteogenic response in osteoprogenitor cel

145 induced-, (ii) electrical field stimulation (EFS)-induced force, (iii) pCa-force, (iv) slack-tests an

146 nse, a program of early feasibility studies (EFS) has been developed.

147 nts who received temsirolimus had a superior EFS compared with bevacizumab.

148 204) had a shorter mean event free survival (EFS) (2.7 versus 8.6 years; p = 0.007 log-rank analysis)

149 LBCL and FL had similar event-free survival (EFS) (hazard ratio [HR] = 0.95) and a trend of better ov

150 Five-year event-free survival (EFS) +/- SE (0.40 +/- 0.01) and overall survival (OS; 0.

151 a risk score to predict event-free survival (EFS) after allogeneic hematopoietic cell transplantation

152 ssociated with improved event-free survival (EFS) and overall survival (OS) in early-stage breast can

153 up, 5.38 years), 5-year event-free survival (EFS) and overall survival (OS) were 62% (95% CI, 52 to 7

154 The 4-year event-free survival (EFS) and overall survival (OS) were 84.7% +/- 2.3% and 8

155 Event-free survival (EFS) and overall survival (OS) were compared between non

156 Event-free survival (EFS) and overall survival (OS) were estimated for the co

157 llow-up of 30.9 months, event-free survival (EFS) and overall survival (OS) were significantly better

158 EN0534 aimed to improve event-free survival (EFS) and overall survival (OS) while preserving renal ti

159 e relationships between event-free survival (EFS) and overall survival (OS) with MRD status in pediat

160 lms tumors (FHWTs) with event-free survival (EFS) and overall survival (OS) within each tumor stage a

161 ds in EF and SF, 5-year event-free survival (EFS) and overall survival (OS), and treatment-related mo

162 ts of cardiotoxicity on event-free survival (EFS) and overall survival (OS).

163 therapy (NAC), and both event-free survival (EFS) and overall survival (OS).

164 The 5-year event-free survival (EFS) and overall survival estimates were 84.3% and 89.2%

165 Four-year event-free survival (EFS) and overall survival estimates were 88% (95% CI, 85

166 rial ACNS0121 estimated event-free survival (EFS) and overall survival for children with intracranial

167 e previously shown that event-free survival (EFS) at 24 months (EFS24) is a clinically useful end poi

168 erall survival (OS) and event-free survival (EFS) at 3 years were 85.7% and 75.8%, respectively.

169 To investigate whether event-free survival (EFS) can be maintained among children and adolescents wi

170 nd favorably influences event-free survival (EFS) compared with historical controls.

171 r patients who achieved event-free survival (EFS) for 12 (EFS12), 24 (EFS24), 36 (EFS36) or 60 (EFS60

172 he primary analysis was event-free survival (EFS) for patients < 36 months of age compared with a coo

173 The median event-free survival (EFS) for the entire study population was 8.4 months; 1-y

174 enting therapy improved event-free survival (EFS) for these patients.

175 ective of the trial was event-free survival (EFS) from randomization.

176 ion failure with 5-year event-free survival (EFS) of 50.7% (95% CI, 37.4 to 64.0) and 5-year overall

177 ve disease had a 5-year event-free survival (EFS) of 53% +/- 5% and a 5-year overall survival (OS) of

178 determine the effect on event-free survival (EFS) of staging variables, extent of resection, and repe

179 The 6-year event-free survival (EFS) rate for all patients enrolled in AALL0331 was 88.9

180 (P = .007), and 5-year event-free survival (EFS) was 51% versus 58% (P = .026).

181 Five-year event-free survival (EFS) was 75.0% in patients with 1q gain (95% CI, 68.5% t

182 of 11.5 months; 5-year event-free survival (EFS) was 77% (range, 62% to 87%).

183 Median event-free survival (EFS) was 78.1 months (95% confidence interval [CI], 41.8

184 l survival was 94%, and event-free survival (EFS) was 91%.

185 2) primary end point of event-free survival (EFS) was evaluated 6 months after completion of patient

186 ar overall survival and event-free survival (EFS) were 95% and 82%, respectively.

187 t differences in OS and event-free survival (EFS) were found when comparing ISM, BMM, and SSM.

188 Event-free survival (EFS), an earlier prostate-specific antigen (PSA)-based c

189 Overall survival (OS), event-free survival (EFS), and disease-free survival (DFS) were 78.2%, 58.1%,

190 overall survival (OS), event-free survival (EFS), and relapse risk from the end of induction 1 (haza

191 he primary endpoint was event-free survival (EFS), and secondary endpoints were toxicity and predicto

192 (ML-DS) have favorable event-free survival (EFS), but experience significant treatment-related morbi

193 points included 5-year event-free survival (EFS), distant disease-free survival (DDFS), overall surv

194 tment outcomes included event-free survival (EFS), overall survival (OS), and cumulative incidence of

195 s associated with worse event-free survival (EFS), overall survival (OS), and cumulative incidence of

196 re-free survival (FFS), event-free survival (EFS), transformation-free survival (TFS), and overall su

197 Primary end points were event-free survival (EFS), treatment discontinuation, no complete response (C

198 actors with HL-specific event-free survival (EFS).

199 sequencing with pCR and event-free survival (EFS).

200 ng associated with poor event-free survival (EFS).

201 The main end point was event-free survival (EFS).

202 e primary end point was event-free survival (EFS).

203 es of interest included event-free survival (EFS).

204 The primary outcome was event-free survival (EFS); defined as no clinical or radiological relapses an

205 Event-free survival (EFS, primary endpoint) and other clinical endpoints and

206 nostic significance for event-free survival (EFS, the main endpoint of the IELSG-19 trial) were age >

207 26%; P = .07) and lower event-free survival (EFS; 4-year EFS, 31% vs 43%; P < .01), but progression-f

208 tment reached excellent event-free survival (EFS; 72% v 65%) and overall survival (OS; 82% v 74%).

209 - 4%; Plog-rank = .64), event-free survival (EFS; 87% +/- 3% vs 89% +/- 4%; Plog-rank = .71), and cum

210 al (OS; P = 0.0441) and event-free survival (EFS; P = 0.0114) compared with low MAP7 expression (MAP7

211 e cell infiltration and event-free-survival (EFS).

212 cellent outcome (5-year event-free survival [EFS] +/- standard deviation [SD], 95% +/- 2%; 5-year ove

213 progression, or death (event-free survival [EFS]) were estimated.

214 v No-GO 34%, P = .731; event-free survival [EFS]: GO 53% v No-GO 58%, P = .456).

215 rimary end points were event-free survivals (EFS).

216 The EFS and OS rates are excellent for this group of patient

217 The EFS committee has developed and implemented processes to

218 The EFS difference reflected a significant difference in the

219 The EFS for patients with ependymoma younger than 3 years of

220 The EFS for SR patients in AAML0631 was noninferior to that

221 The EFS hazard ratio (HR) for achieving MRD negativity is 0.

222 The EFS in our MS cohort is significantly greater than other

223 The EFS was 5.7 months for patients with prior bortezomib ex

224 Conclusion The EFS rate for children with IR MGCT observed after three

225 y LN sampling seems to have no impact on the EFS and should not be recommended.

226 oc analysis, we also compared results to the EFS rate of comparable patients treated with four cycles

227 but not BIBN4096bs increased contraction to EFS in the absence of suramin and prazosin.

228 uplication-negative patients with respect to EFS and CIR.

229 on the frequency-maximal force responses to EFS in isolated ileal tissues.

230 ICC-IM responses to EFS were ablated by inhibiting Ca(2+) stores with cyclop

231 The Native TPV EFS (Early Feasibility Study) is a prospective, multicen

232 Three-year results from the Native TPV EFS revealed stable Harmony TPV device position, good va

233 ntemporary Children's Oncology Group trials, EFS did not differ by race/ethnicity; however, adjusted

234 After 94.5 months of follow-up, EFS was significantly lower in the celecoxib group (haza

235 The primary outcome was EFS from randomization to the occurrence of the first ev

236 the evaluated variables was associated with EFS after correction for multiple testing, but this anal

237 UVmax was also significantly associated with EFS both in patients receiving SIM (P= 0.028) and in tho

238 Associations with EFS (ie, freedom from disease progression or recurrence)

239 A total of 36 studies with EFS by pCR status representing 5768 patients with HER2-p

240 endent prognostic factors predicting a worse EFS.

241 ing associated with an inferior outcome (5-y EFS, 39.2% +/- 4.7% [CS </= 2] vs. 16.4% +/- 4.2% [CS >

242 nificant outcome difference by CS noted (5-y EFS, 43.0% +/- 5.7% [CS </= 12] vs. 21.4% +/- 3.6% [CS >

243 Although the 1-year EFS met the prespecified target of >/=75%, this regimen

244 The 2-year EFS for all patients was 0.98 (95% CI, 0.96 to 0.99).

245 was 0.96 (95% CI, 0.89 to 0.98), and 2-year EFS for patients without HRFs for which observation was

246 The 2-year EFS rate with ibrutinib was 80% (95% confidence interval

247 CT PET were independently prognostic; 3-year EFS for pre-ASCT PET-positive patients with low bMTV was

248 s with two or more risk factors had a 3-year EFS of 20% (95% CI, 11% to 30%).

249 one or bone marrow involvement) had a 3-year EFS of 69% (95% CI, 52% to 82%); high-risk patients with

250 o Oberlin risk factor had an improved 3-year EFS of 69% on ARST0431 compared with an historical cohor

251 donor were at the lowest risk with a 3-year EFS of 92% (score, 0).

252 of 30 months (95% CI, 22-38 months); 3-year EFS was 59% (95% CI, 54%-65%).

253 disease identified a favorable group (3-year EFS, 100%).

254 tched unrelated donor were high risk (3-year EFS, 57%; score, 2 or 3).

255 ated donor were at intermediate risk (3-year EFS, 87%; score, 1).

256 patients enrolled from 2003 to 2011, 4-year EFS (EFS4) rate was 89% (95% confidence interval, 83% to

257 ed prolonged chemotherapy; on NWTS-5, 4-year EFS for all children with BWT was 56%.

258 The 4-year EFS for patients with stage I/II and stage III/IV diseas

259 was powered to detect a reduction in 4-year EFS from 87% to 75% and overall survival from 95% to 88%

260 oved compared with the NWTS-5 updated 4-year EFS of 68.8% for patients with stage I/II disease (P = .

261 In contrast, the 4-year EFS was only 74% in patients with combined positive lymp

262 ) and lower event-free survival (EFS; 4-year EFS, 31% vs 43%; P < .01), but progression-free survival

263 razoxane-exposed patients had similar 5-year EFS (49.0% v 45.1%; P = .534) and OS (65.0% v 61.9%; P =

264 ny detectable level who had excellent 5-year EFS (98.1%) and OS (100%).

265 s (SCAs); only 1p loss decreased EFS (5-year EFS +/- SD in patients 1p loss and no 1p loss, 62% +/- 1

266 est marker (11q loss and no 11q loss: 5-year EFS +/- SD, 48% +/- 16% and 85% +/- 7%, P = .033; 5-year

267 had a reduced EFS in both age groups (5-year EFS +/- SD, 84% +/- 3% in patients < 18 months of age an

268 HTS and FC showed similar 5-year EFS and OS for MRD-positive and -negative patients using

269 r greater at the end of induction had 5-year EFS and OS of 26.7% +/- 9.3% and 29.3% +/- 10.1%, respec

270 HSCT were not significantly improved: 5-year EFS and OS were 57.4% +/- 7.0% and 66.2% +/- 6.6% compar

271 Unadjusted 5-year EFS and OS were 83% (SE, 1.2%) and 97% (SE, < 1%), respe

272 The 5-year EFS and OS were both 89% (95% CI, 67 to 100) for desmopl

273 The 5-year EFS for stages IIb, III, and IV were 100%, 82.8%, and 82

274 and a low EOI MRD level (< 0.01%) had 5-year EFS of 100%.

275 1 of 2,633) had high MRD (>/= 5%) and 5-year EFS of 47.0% (95% CI, 32.9 to 61.1), which was similar t

276 33 patients) of the trial cohort with 5-year EFS of 48.0% (95% CI, 39.3 to 58.6).

277 k patients had a significantly higher 5-year EFS rate (88%, SE 2%) with therapy intensification (incl

278 erall outcome improved significantly (5-year EFS rate 87%, 5-year survival rate 92%, and 5-year cumul

279 The 5-year EFS rates differed significantly by tumor grade (P = .00

280 The 5-year EFS rates in the low-, intermediate-, and high-risk grou

281 The 5-year EFS rates were 61.4% (95% CI, 34.5% to 89.6%), 37.2% (95

282 PF was 46% versus 69% (P < .001), and 5-year EFS was 36% versus 56% (P < .001).

283 For 204 eligible patients, 5-year EFS was 89.9% and overall survival (OS) was 93.0%.

284 with a median follow-up of 64 months, 5-year EFS was not statistically significantly different betwee

285 ly higher with CME compared with IME (5-year EFS, 0.33 +/- 0.03; 5-year OS, 0.37 +/- 0.03; P < .001 a

286 e still superior with CME versus IME (5-year EFS, 0.47 +/- 0.02 v 0.39 +/- 0.04; P = .038); CILP was

287 Poor early treatment response (5-year EFS, 58% +/- 16% vs 88% +/- 3%; Plog rank = .0008) and g

288 16% +/- 7% vs 3% +/- 2%, PGray = .02; 5-year EFS, 73% +/- 8% vs 91% +/- 4%, Plog rank = .018) were id

289 HR, 0.79; 95% CI, 0.63-0.99; P = .04; 5-year EFS, 86.7% vs 82.1%).

290 Eight-year EFS was 77% for those with 1q gain and 90% for those lac

291 Eight-year EFS was 86% (95% CI, 84% to 88%) for the entire cohort.

292 Five-year EFS and OS were 52.2% +/- 4.9% and 58.9% +/- 4.8%, respe

293 Five-year EFS for the entire cohort was 85.5% (95% CI, 79.2% to 90

294 Five-year EFS, OS, and CILP (+/- SE) were 43.5% +/- 3.7%, 54.9% +/

295 Four-year EFS and overall survival for the entire cohort were 37%

296 Three-year EFS from the time of randomization was 61.6% (95% CI, 54

297 Two-year EFS for patients with HRFs requiring adjuvant chemothera

298 gnificantly associated with poorer five-year-EFS (25.0%. vs. 69.4%, p = 0.014).

299 0.031) were associated with worse five-year-EFS.

300 At 4 years, EFS was 63.7% for ABVD8 versus 69.3% for BEACOPP4+4 (haz